$VRCI Website = http://verdescienceinc.com/
Leading Cutting Edge Research for the Isolation of Highly effective Formulations for the Treatment of Chronic Medical Disorders
Verde Science (VRCI-OTCQB) has assembled an impressive team of scientists from highly technical disciplines including Bioprocess Technology, Nanotechnology, Molecular Virology and Immunology, Molecular Biology, Pharmacology and Medical Device Design. Our focus is the discovery of novel drugs and new treatment modalities, as well as cutting edge diagnostic devices and pharmaceutical delivery systems for the treatment of emerging diseases and contemporary medical issues where current treatments either do not exist or are inadequate.
An initial focus is on developing custom medicinal formulations from cannabinoids and THC compounds for the treatment of specific issues such as migraines, glaucoma, loss of appetite from cancer therapies, and numerous other medical issues. Verde also plans to alpha test innovative growing technologies in India as part of the company’s initiatives.
Alliance Partners – Research & Development
Currently the company is working on starting a Research and Development initiative in Canada upon becoming licenced. In the meantime, the company is beginning a THC Pharmaceutical Development Program to be run through its alliance with the Institute of Chemical Technology in Mumbai, India. The program will include executing comprehensive research to develop specific, custom formulations and novel delivery mechanisms for cannabinoid and THC based drugs.
Institute of Chemical Technology, Mumbai, India
The Institute of Chemical Technology (ICT), Mumbai, is India’s premier chemical engineering and technology research institute. The institute is dedicated to training and research in various branches of Chemical Engineering, Chemical Technology, and Pharmacy. Over the last 76 years it has acquired the status of being the premier and renowned institute of Chemical Technology in the country. Research has been an integral part of ICT since its inception and it has created over 500 first generation entrepreneurs. The ICT has brought considerable international recognition to India, and its stellar performance is reflected in the following: 1. The MHRD had evaluated all deemed universities in the country in 2009 rated ICT as Number One Deemed University with “A” grade. 2. The ICT has also been rated as Number One Institute by NPIU among 127 TEQIP funded Institutes, all over India, in October, 2010.
Sterkem Pharma Group of Companies
The Sterkem Pharma Group of Companies was established in 1974 and has continued to market quality pharmaceuticals for over a third of a century. The family based enterprise has been a brand leader for Anti-arthritic drugs viz. Inmecin (Indomethacin) and its allied products. Injectable formulations, both powder and liquid were among the first products marketed by Sterkem. Today their marketing domain includes Anti-arthritic, Antidepressants, Analgesics, Antibiotics, and a range of Gynaecological and Obstetric drugs in different formulations. The most recent additions to their range of products are Multi-Vitamins, Anti-oxidants and Nutritional Supplements that strengthen the immune system.
Directors and Management Team
Harp Sangha – Chairman / CEO
Mr. Sangha has been a founder, CEO and board member of several public companies and brings 27 years of entrepreneurial, operational and capital market experience to Verde Science. In 1986 he started his career as Investment Advisor and gained his affinity for raising capital for numerous startups and early stage public companies. Mr. Sangha departed this position in March 2006 to apply his unique ability of bringing capital to early stage projects and founded Douglas Lake Minerals. In the role of CEO, his leadership in Douglas Lake overcame rigorous operational challenges in the African environment and brought the value of the company to $240 million. He has also served as CEO, Secretary, and director of Sharprock Resources Inc. (OTCBB: SHRK) where he raised capital to explore a preproduction gold project in the Chukotka Region of Russia. He joined Rango Energy, Inc. in 2012 as Chairman of the Board and Chief Executive Officer. Mr. Sangha has established many valuable contacts and relationships with institutional clients worldwide.
David Alexander, CA, BComm – Chief Financial Officer
Mr. Alexander is a chartered accountant who graduated from the University of British Columbia with a BComm in Finance. He has managed the rapid growth of several early stage startup companies to major successes in their respective sectors. As CFO of the start-up Nortran Pharmaceuticals, Inc., a University of British Colombia based pharmaceutical research and development company engaged in the development and commercialization of cardiovascular therapies, he assisted in obtaining its initial financing and first discoveries. While at Nortran he worked closely with Dr. Walker and a group of scientists who had a vision to create solutions for life threatening arrhythmias of the heart, acute cough, and pain management. Nortran subsequently became Cardiome Pharma Corp., a successful Vancouver BC based pharmaceutical company listed on Nasdaq: CRME. While CFO of Arakis Energy Corporation, he managed its growth from startup to over a billion dollars in assets, and moved its public company listing from the Vancouver Stock Exchange to Nasdaq in New York. Arakis was an international oil and gas development company with wells in Kentucky, Oman, New Guinea and the Sudan. The company was subsequently sold to Talisman Energy Inc. and oil fields developed by Arakis have resulted in proven developed and undeveloped reserves of over 500 million barrels. The fields have been producing over 350,000 barrels per day for the last 15 years. During his tenure as CFO and controller at Columbia Trust Company, he managed the growth of its assets from $50 million to over $1 billion during a 5-year period. He implemented a comprehensive management system that enabled him to reduce administrative staff from 50 to 15, and managed a $20 million money market and stock portfolio. David left Columbia Trust when it was sold to a Toronto based trust company.
Craig Alford, MSc – Independent Director
Mr. Alford holds a Master of Degree of Science. He has worked throughout North and South America, China, several Central Asian Republics, Russia, Australia and Africa. This experience has included independent consulting assignments, and positions within the management of major and junior company exploration companies. Mr. Alford has assisted the World Bank and the China-Africa Development Fund in tax policy and investment risk. He has been responsible for budgeting and the expenditure of hundreds of millions of dollars and has developed comprehensive economic analysis for billion dollar M & A transactions. Mr. Alford has worked as a consultant for Conoco Philips (COP:NYSE), China Railway (SHA:601390), and Teck Mining Ltd (NYSE:TCK). He has served as a director and Vice President in numerous junior companies and has played a key role in successfully raising over $40 million in equity.
Manit Patel, BPharmSc., MBA – Chief Technology Officer
Mr. Patel earned a Bachelor in Pharmaceutical Sciences from The Institute of Chemical Technology in Mumbai, India, and an MBA from Queensland University of Technology in Brisbane, Australia. He was Director of Business Development for Sterkem Group, a Mumbai, India based pharmaceutical R&D, production, and marketing firm. At Sterkem he was responsible for business strategy and new product development, reporting directly to the Board of Directors. He successfully restructured the marketing and manufacturing operations to improve profitability. He was responsible for training a sales team of 150 sales representatives including 15 province managers. Subsequently, he was a market research manager at iData Research, an international market research consulting company dedicated to the provision of business intelligence for the medical device, dental and pharmaceutical industries. He managed global accounts for business development and consulting for cardiovascular devices and therapies. He built relationships with existing and new clients, and enhanced the growth potential of the company by working with the Analyst Team for new product development. Mr. Patel has a broad network of international business contacts throughout the pharmaceutical sector, which will be an important resource for Verde Science as it moves forward with its growth plans. He is a creative problem solver with focus on strategic planning to ensure continuous long-term success. He excels at business development by building relationships and engaging C-Level decision makers and his excellent interpersonal skills help him relate to culturally diverse audiences and managing staff in different countries across numerous time zones.
Dr. Shantesh Hede, Ph.D. – Director of Product Development
Dr. Hede heads Verde Science’s R&D programs and is based in Mumbai, India, where he directs the program on-site with Verde’s Research and Development partner, the Institute of Chemical Technology. He earned a Ph.D. in Bioengineering Systems from the MIT Portugal Program, a Master of Engineering Management from Duke University, and a Bachelor in Pharmaceutical Sciences from the Institute of Chemical Technology. Dr. Hede’s focus is to leverage the R&D platform alliances with existing partners in healthcare institutions, academia and the pharmaceutical industry for the identification and commercialization of specific formulations derived from the marijuana plant for the treatment of numerous medical conditions. His focus is to ensure Verde’s scientific activities develop applications that will produce significant intellectual property in areas of limited market competition to generate substantial value for company shareholders.
Louis Silver – Director of Investor Relations and Corporate Development
Louis brings a record of success in both Fortune 500 companies and the entrepreneurial arena. After completing graduate school Louis held several corporate finance positions at International Utilities, Inc., including Director of Cash Management and Banking Relations and Senior Financial Analyst. He had several management roles while with Aramark, Inc., including Vice President of Administration, Senior Vice President of the Leisure Services Division, and President of the Public Vending Division. Silver was founder of AAA Building Maintenance, Inc. a regional service company with 500 employees that was sold to Allegheny Beverage Corporation, and later founder and managing Director of Montgomery Capital Advisors, a boutique investment banking firm. Louis earned an MBA from Temple University, completed Ph.D. studies in marketing, and earned an M.A. in theology from the Palmer Theological Seminary of Eastern University. He has served on numerous local philanthropic boards, including Montgomery County D.A.R.E., Big Brothers/Big Sisters, Baptist Children’s Service, ASSETS Montgomery County (regional microenterprise development program) Palmer Theological Seminary, and the Sheriff of Montgomery County Advisory Board.
Paul Pelosi, Jr. – Advisor
Paul Francis Pelosi, Jr. is a speaker on environmental policies that encourage individuals and local governments to take a more active role in conserving natural resources and reducing carbon footprints. Pelosi has spoken at conferences in Stockholm, Milan, and Amsterdam. Pelosi is a contributor to the anthology Inside the Minds: Navigating Green Construction and Energy Initiatives, forthcoming from Aspatore Books in Spring 2009. Pelosi is a graduate of Georgetown University with a Bachelor of Arts in History (Cum Laude, 1991) and a JD/MBA (Joint Degree 1995) with an emphasis in International Business. In 1991, Pelosi was a Gillette All Star Athlete in Track and he received the Georgetown International Human Rights Award in 1994. Paul Pelosi has 16 years’ experience in advising emerging and Fortune 500 companies in the areas of finance, infrastructure, sustainability and public policy. Pelosi is a founding member of Cisco Connected Urban Development and under the direction of Cisco CEO John Chambers, Pelosi worked with San Francisco, Birmingham, Amsterdam, Hamburg, Lisbon, Madrid and Seoul to attempt to demonstrate how network connectivity might reduce carbon emissions in urban environments. In 2003, Pelosi was appointed by San Francisco Mayor Willie Brown to the city’s Commission on the Environment. The commission is responsible for developing policies and programs in recycling, toxics reduction, environmental justice, energy efficiency, commute alternatives, climate change, and the city’s urban forest. Pelosi served as President of the Commission. During his tenure, San Francisco implemented energy efficiency programs that resulted in a reduction of 28 megawatts of electricity, created programs that increased residential and commercial recycling from 46% to 70%, as well reduced San Francisco’s carbon emissions to 6% below 1990 levels, and became the first municipality to implement a ban on plastic bags. Currently, Pelosi serves as Senior Vice President of Business Development at InfoUSA where he is responsible for identifying acquisitions and organizing programs to develop effective strategy for reducing waste and promoting greener practices in the market research industry. Pelosi also advises companies including NASA Ames Research Center and AirPatrol Corporation on a variety of infrastructure projects to promote both sustainable development and security. Prior to independent consulting, Pelosi served many years with Bank of America Securities, Bank of America Countrywide and JP Morgan – Chase Manhattan where he worked in Corporate Finance, Institutional Sales, and the Residential Mortgage Industry. Pelosi has been a member of the California State Bar since 1996.
Sam Sangha – Global Corporate Development
Mr. Sangha began his career as an investment advisor at Global Securities Corporation in 2004 and focused on the natural resource and mining sector where he worked till 2010. Over that period Mr. Sangha built a network of retail and institutional investors across North America and Europe. Mr. Sangha left Global Securities in 2010 and joined Douglas Lake Minerals as head of Investor Relations/Corporate Development. While working at Douglas Lake Minerals, Mr. Sangha focused on financing, investor presentations, and corporate relations. Mr. Sangha currently holds this position with Verde Science.
The Canadian Market
Verde Science’s focus is the Canadian markets, where medical marijuana is legal if patients have a doctor’s prescription. As a new entrant into the Canadian market, Verde Science will bring much more than economy of scale, with it’s new, technology-driven approach that could be a game changer. Most of Canada, lacks strong corporate players in the research and product development (including aeroponic technology) of medical marijuana remedies.
Medical Marijuana Regulation in Canda
The regulation on access to cannabis for medical purposes, established by Health Canada in July 2001, defines two categories of patients eligible for access to medical cannabis. BC College of Physicians and Surgeons’ recommendation, as well as the CMPA position, is that physicians may prescribe cannabis if they feel comfortable doing. The MMAR forms are a confidential document between Health Canada, the physician and the patient. The information is not shared with the College or with the RCMP. No doctor has ever gone to court or faced prosecution for filling out a form or for prescribing medical cannabis.
Covers any symptoms treated within the context of providing compassionate end-of-life care or at least one of the symptoms associated with the following medical conditions:
- Severe pain and/or persistent muscle spasms from multiple sclerosis, from a spinal cord injury, from spinal cord disease
- Severe pain, cachexia, anorexia, weight loss, and/or severe nausea from cancer or HIV/AIDS infection
- Severe pain from severe forms of arthritis
- Seizures from epilepsy
Is for applicants who have debilitating symptoms of medical conditions, not covered in Category 1. The application of eligible patients must be supported by a medical practitioner. Health Canada permits marijuana for approved patients who can demonstrate a medical need for compassionate end-of-life care or debilitating symptoms.
Verde Science has assembled a highly experienced, well-funded team that will deploy state-of-the-art research technology and the superior growing methodology of aeroponics to enter and take a meaningful market share. The company is launching its THC Pharmaceutical Development Program by executing a comprehensive research program which involves developing custom formulations preparing protocols for clinical trials which will initially be conducted through its partnership alliance with a pharmaceutical company in Mumbai, India.
Verde Science plans to develop specific, custom formulations and novel delivery mechanisms for cannabinoid and THC based drugs for a variety of ailments including chronic pain, inflammation, migraines, seizures related to epilepsy, nausea associated with cancer treatment, and numerous others. The company then plans to then conduct clinical trials in Canada after it obtains its Canadian R&D license.
With consistent, highly efficient production of clean product with no pesticides grown in environmentally friendly surroundings using recycled water, and custom cannabinoid formulations with novel delivery mechanisms, Canada will soon be introduced to the “Tesla” of medical marijuana.
Marijuana Grown with Aeroponics Aeroponics is the process of growing plants in an air or mist environment without the use of soil or an aggregate medium (known as geoponics). The word “aeroponic” is derived from the Greek meanings of aero- (air) and ponos (labor). Aeroponic culture differs from conventional hydroponics, aquaponics, and in-vitro (plant tissue culture) growing. Unlike hydroponics, which uses a liquid nutrient solution as a growing medium and essential minerals to sustain plant growth; or aquaponics, which uses water and fish waste, aeroponics is conducted without a growing medium. Because water is used in aeroponics to transmit nutrients, it is sometimes considered a type of hydroponics.
Filings and Financials
SEDAR is the official site that provides access to public securities documents and information filed by public companies and investment funds with the Canadian securities regulatory authorities in the SEDAR filing system. The statutory objective in making public this filed information is to enhance investor awareness of the business and affairs of public companies and investment funds and to promote confidence in the transparent operation of capital markets in Canada. Achieving this objective relies heavily on the provision of accurate information on market participants. Public regulatory filings are now accessible on SEDAR.com within fifteen minutes of the original submission through the SEDAR filing system.
Go to this link to view all of the company’s public filings:
Verde Science, Inc. Filings and Financials
SEC Filings – OTC Markets
To view our filings on the OTC Markets website, please go to this page…
To view our financials on the OTC Markets website, please go to this page…
Verde Science Inc.
Email: [email protected]
Investor Relations Contact:
Email: [email protected]
Exclusive Interview: Nancy Pelosi's son working with medicinal marijuana company $VRCI ------> https://youtu.be/PrDZRtUbbqY <------
Daily Chart: Weekly Chart: